Get the Stockscreener App
0.196
2.00%
-0.004
After Hours:
.20
0.004
+2.04%
Viracta Therapeutics Inc stock is traded at $0.196, with a volume of 433.60K.
It is down -2.00% in the last 24 hours and down -15.88% over the past month.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
See More
Previous Close:
$0.20
Open:
$0.2046
24h Volume:
433.60K
Relative Volume:
0.39
Market Cap:
$7.70M
Revenue:
-
Net Income/Loss:
$-51.06M
P/E Ratio:
-0.142
EPS:
-1.38
Net Cash Flow:
$-40.03M
1W Performance:
-11.23%
1M Performance:
-15.88%
6M Performance:
-75.81%
1Y Performance:
-71.25%
1-Day Range:
$0.191
$0.2046
1-Week Range:
$0.1815
$0.2176
52-Week Range:
$0.1815
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Name
Viracta Therapeutics Inc
Sector
Industry
Phone
858-400-8470
Address
2533 S COAST HWY 101, CARDIFF
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-22 | Initiated | RBC Capital Mkts | Outperform |
| May-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Initiated | SVB Leerink | Outperform |
| Mar-25-21 | Initiated | Evercore ISI | Outperform |
Viracta Therapeutics Inc Stock (VIRX) Latest News
Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Perhaps timely catching Viracta Therapeutics Inc (VIRX) would be a good idea - SETE News
Biopharma Layoff Tracker 2024: Lykos, Galera, Grail and More Cut Staff - BioSpace
Examining Viracta Therapeutics Inc (VIRX) stock is warranted - US Post News
Viracta Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Stock Surge: Viracta Therapeutics Inc (VIRX) Closes at 0.31, Marking a -11.76 Increase/Decrease - The Dwinnex
Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Downgraded by SVB Leerink to “Market Perform” - Defense World
What is Viracta Therapeutics Inc (VIRX) Stock Return on Shareholders’ Capital? - SETE News
Viracta Therapeutics stock PT lowered by RBC amid pipeline strategy shift - Investing.com Canada
Viracta reports progress in PTCL treatment trial By Investing.com - Investing.com Australia
Sunesis: Q2 Earnings Snapshot - San Antonio Express-News
Viracta reports progress in PTCL treatment trial - Investing.com
A Closer Look at Viracta Therapeutics Inc (VIRX) Stock Gains - The InvestChronicle
VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q2 2024 - MSN
VIRX stock touches 52-week low at $0.38 amid market challenges - Investing.com Canada
New CEOs and positive earnings have these stocks moving - RagingBull
Viracta Therapeutics Announces Positive Data from the Phase - GlobeNewswire
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday? - Benzinga
Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today? - InvestorPlace
Viracta stock jumps after corporate update (NASDAQ:VIRX) - Seeking Alpha
VIRXViracta Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - StockTitan
Are Viracta Therapeutics Inc’shares a good deal? - US Post News
Daily Market Movement: Viracta Therapeutics Inc (VIRX) Sees a 0.59 Increase, Closing at 0.44 - The Dwinnex
VIRX stock touches 52-week low at $0.43 amid market challenges - Investing.com
Viracta Therapeutics announces workforce reduction - Investing.com
Short Interest in Viracta Therapeutics, Inc. (NASDAQ:VIRX) Grows By 35.2% - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $28.09 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Trading Down 1.1% - Defense World
Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement - Quantisnow
Viracta Therapeutics (NASDAQ:VIRX) Stock Price Down 1.8% - Defense World
Can Viracta Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Viracta Therapeutics Announces New Employment Inducement Grant - Quantisnow
Viracta Therapeutics to Present at Upcoming May Investor Conferences - Quantisnow
Viracta Therapeutics to Present at the Jefferies Healthcare Conference - Quantisnow
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the ... - Quantisnow
Viracta Therapeutics Inc Stock (VIRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viracta Therapeutics Inc Stock (VIRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pomerantz Roger | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
117,444 |
| Pomerantz Roger | Director |
May 25 '24 |
Option Exercise |
0.00 |
9,035 |
0 |
108,410 |
| ROYSTON IVOR | Director |
May 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
789,303 |
| ROYSTON IVOR | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
764,084 |
| Pomerantz Roger | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
99,375 |
| Chevallard Daniel R. | CFO and COO |
Feb 25 '24 |
Option Exercise |
0.00 |
6,889 |
0 |
105,711 |
| Chevallard Daniel R. | CFO and COO |
Feb 27 '24 |
Sale |
0.73 |
3,405 |
2,493 |
102,306 |
| Rothera Mark | President and CEO |
Nov 30 '23 |
Buy |
0.49 |
52,094 |
25,734 |
52,094 |
| Rothera Mark | President and CEO |
Dec 01 '23 |
Buy |
0.49 |
47,906 |
23,627 |
100,000 |
| Chevallard Daniel R. | CFO and COO |
Nov 25 '23 |
Option Exercise |
0.00 |
6,889 |
0 |
102,542 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):